Wed, Aug 27, 2014, 11:52 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

  • mcj96 mcj96 Aug 15, 2013 5:01 PM Flag

    Why should AMGN buy ONXX at a whopping 9.6x 2014 rev estimates(Yahoo) vs.... LESS than 1x for ....S V N T ?

    And SVNT's orphan drug is already approved in both the US & EU and has enormous pricing-power going forward. For ex., SVNT's orphan rare disease therapy Krystexxa is currently priced at only $5,390/dose vs over $34,000/dose for similar rare disease therapies like Acthar. In addition, Krystexxa has label expansion opportunities in 1)Organ Transplant , 2)Dialysis, 3)Induction Maintenance and 4)Tumor Lysis Syndrome. SVNT is worth a minimum of $5-$6/sh by YE after they align Krystexxa's price to rare disease levels. Good luck to all.

 
ONXX
124.700.00(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TubeMogul, Inc.
NasdaqGSWed, Aug 27, 2014 4:00 PM EDT
Williams-Sonoma Inc.
NYSEWed, Aug 27, 2014 4:01 PM EDT